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Kaposi Sarcoma Herpesvirus Induces HO-1 during De Novo Infection
of Endothelial Cells via Viral miRNA-Dependent and -Independent
Mechanisms
Sara Botto,a Jennifer E. Totonchy,b Jean K. Gustin,a Ashlee V. Mosesa
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USAa; Department of Pathology and Laboratory Medicine, Weill Cornell
Medical College, New York, New York, USAb
ABSTRACT Kaposi sarcoma (KS) herpesvirus (KSHV) infection of endothelial cells (EC) is associated with strong induction of
heme oxygenase-1 (HO-1), a stress-inducible host gene that encodes the rate-limiting enzyme responsible for heme catabolism.
KS is an angioproliferative tumor characterized by the proliferation of KSHV-infected spindle cells, and HO-1 is highly ex-
pressed in such cells. HO-1 converts the pro-oxidant, proinflammatory heme molecule into metabolites with antioxidant, anti-
inflammatory, and proliferative activities. Previously published work has shown that KSHV-infected EC in vitro proliferate in
response to free heme in a HO-1-dependent manner, thus implicating virus-enhanced HO-1 activity in KS tumorigenesis. The
present study investigated the molecular mechanisms underlying KSHV induction of HO-1 in lymphatic EC (LEC), which are
the likely spindle cell precursors. In a time course analysis of KSHV-infected cells, HO-1 expression displays biphasic kinetics
characterized by an early transient induction that is followed by a more sustained upregulation coincident with the establish-
ment of viral latency. A viral microRNA miR-K12-11 deletion mutant of KSHV was found to be defective for induction of HO-1
during latency. A potential mechanism for this phenotype was provided by BACH1, a cellular HO-1 transcriptional repressor
targeted by miR-K12-11. In fact, in KSHV-infected LEC, the BACH1 message level is reduced, BACH1 subcellular localization is
altered, and miR-K12-11 mediates the inverse regulation of HO-1 and BACH1 during viral latency. Interestingly, the data indi-
cate that neither miR-K12-11 nor de novo KSHV gene expression is required for the burst of HO-1 expression observed at early
times postinfection, which suggests that additional virion components promote this phenotype.
IMPORTANCE While the mechanisms underlying KSHV induction of HO-1 remain unknown, the cellular mechanisms that regu-
late HO-1 expression have been extensively investigated in the context of basal and pathophysiological states. The detoxifying
action of HO-1 is critical for the protection of cells exposed to high heme levels. KS spindle cells are erythrophagocytic and con-
tain erythrocyte ghosts. Erythrocyte degeneration leads to the localized release of heme, creating oxidative stress that may be
further exacerbated by environmental or other cofactors. Our previous work showed that KSHV-infected cells proliferate in re-
sponse to heme and that this occurs in a HO-1-dependent manner. We therefore hypothesize that KSHV induction of HO-1 con-
tributes to KS tumor development via heme metabolism and propose that HO-1 be evaluated as a therapeutic target for KS. Our
present work, which aimed to understand the mechanisms whereby KSHV induces HO-1, will be important for the design and
implementation of such a strategy.
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Kaposi sarcoma herpesvirus (KSHV, also known as human her-pesvirus 8), an oncogenic gamma-2 herpesvirus, is the etio-
logic agent of the multifocal endothelial tumor known as Kaposi
sarcoma (KS). KSHV infection can also result in primary effusion
lymphoma (PEL), an aggressive non-Hodgkin B cell lymphoma,
or multicentric Castleman disease, a systemic lymphoproliferative
disorder (1–4). KSHV establishes persistent viral infection in en-
dothelial and B cell targets by actively suppressing apoptosis and
escaping immunodetection through various immune system eva-
sion strategies (5, 6). These survival mechanisms are thought to
contribute to host cell transformation and tumor development.
We previously showed that de novo KSHV infection of human
dermal microvascular endothelial cells (DMVEC) leads to up-
regulation of cellular heme oxygenase-1 (HO-1), a phenotype that
is validated by the robust HO-1 expression observed in spindle
cells in KS biopsy specimens (7, 8). Two functional HO isoforms,
stress-inducible HO-1 and constitutive HO-2, have been identi-
fied. The HO-1 enzyme catabolizes heme into carbon monoxide,
ferrous iron, and biliverdin. Regarding expression kinetics, HO-1
shows ubiquitous tissue distribution and is rapidly and strongly
induced in response to various cellular stresses (9, 10). HO-1 is
also highly expressed in several types of cancer. In the tumor set-
ting, HO-1 is thought to contribute to cytoprotection, prolifera-
tion, and angiogenesis via the conversion of pro-oxidant, cyto-
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toxic heme into metabolites with antioxidant, proangiogenic,
antiapoptotic, and anti-inflammatory activities (10–15). Our pre-
vious work demonstrated that KSHV-infected DMVEC prolifer-
ate in response to low-dose heme and are protected from high-
heme toxicity. We further showed that the proliferative and
survival advantages of KSHV-infected EC were neutralized when
HO-1 enzymatic activity was inhibited (7), suggesting an impor-
tant role for the enzyme in KS pathophysiology. Despite an exten-
sive body of literature describing the cellular regulation of HO-1
expression in both normal and pathological states (16–18), the
mechanism(s) of HO-1 induction by KSHV remains to be de-
fined.
MicroRNAs (miRNAs) are small noncoding RNA molecules
that regulate gene expression post-transcriptionally. miRNAs are
encoded by both animal and plant cells, as well as by the viruses
that infect them (19, 20). Within the KSHV latency-associated
region (KLAR) is encoded a set of viral proteins critical for the
maintenance of the viral episome and for KSHV oncogenesis (21).
Also encoded within the KLAR is a set of 12 miRNAs. Among
these, miR-K12-11 is known to target the mRNA encoding the
HO-1 transcriptional repressor BACH1 (22, 23). BACH1 is a tran-
scriptional repressor of genes such as HO-1 that participate in the
NRF2-dependent oxidative stress pathway (24). Under normal
physiological conditions, NRF2 is prevented from entering the
nucleus and activating transcription. However, under conditions
of oxidative stress, NRF2 enters the nucleus and binds to the an-
tioxidant response elements (AREs) found upstream of 200 an-
tioxidant and cytoprotective genes (25), thereby activating their
transcription. For a subset of these genes, BACH1 functions to
counter NRF2 activation; under nonstress conditions, BACH1
binds to AREs, repressing the transcription of the associated
genes. Interestingly, BACH1 is a heme-binding protein, which
allows it to function as a heme sensor. Thus, above a toxic heme
concentration, heme binds to BACH1 and causes BACH1 to dis-
engage from the ARE, thereby alleviating HO-1 repression and
allowing heme degradation (26, 27). BACH1 is then exported
from the nucleus and degraded within the cytoplasm (28, 29).
Targeting of the BACH1 mRNA by miR-K12-11 thus enables
KSHV to lower BACH1 levels, thereby deregulating oxidative
stress pathways and facilitating infected-cell survival. Notably,
miR-K12-11 exhibits high homology with cellular miR-155,
which is also known to regulate BACH1. Cellular miR-155 is ob-
served to be overexpressed in several types of B-cell lymphoma,
and its ectopic expression in mice causes B-cell malignancies (30).
Because cellular miR-155 and viral miR-K12-11 contain the same
seed sequence (nucleotides 2 to 7 of the miRNA) required for their
interaction with mRNAs, the two miRNAs have many targets in
common, including BACH1 (22, 23, 31, 32). Interestingly, miR-
155 levels are not altered by KSHV infection, which suggests that
miR-K12-11 functions in part by disrupting the regulation of host
genes that are normally controlled by miR-155 (31). Several re-
ports have described miR-K12-11 activity and function in both
ectopic expression and non-endothelial in vitro infection systems
(22, 23, 33). Additionally, miR-K12-11 has been shown to upregu-
late the expression of xCT, an amino acid transport protein sub-
unit encoded by another ARE-containing gene, in EC, thereby
protecting them from oxidative stress (34). However, the poten-
tial influence of miR-K12-11 on HO-1 during de novo infection of
EC has yet to be investigated.
In the present study, we explored the mechanisms whereby
KSHV upregulates HO-1 in lymphatic EC (LEC) at both early
times postinfection and following the establishment of viral la-
tency. We demonstrate that miR-K12-11 is one of the viral com-
ponents responsible for HO-1 upregulation during latency and
that HO-1 is transiently upregulated during the early phase of de
novo infection via a mechanism that is independent of miR-
K12-11 activity. We further show that miR-K12-11 targeting of
the mRNA encoding the HO-1 transcriptional repressor BACH1
contributes to HO-1 induction during latency.
RESULTS
KSHV infection modulates HO-1 expression in LEC in a bipha-
sic manner. We previously reported the upregulation of HO-1
expression in both primary and immortalized DMVEC latently
infected with wild-type (WT) KSHV (7, 8). Using a recently de-
veloped KSHV bacterial artificial chromosome (BAC) system
(KSHV-BAC16), we have confirmed the robust induction of
HO-1 in LEC infected with BAC-derived recombinant KSHV
(35). Considering both the recent recognition that LEC are the
likely precursors of KS spindle cells and reports that KSHV in-
duces lymphatic reprogramming of blood vascular EC (36–40),
we decided to perform mechanistic studies with recombinant
KSHV in lymphatic-lineage EC. We elected to use immortalized
LEC (iLEC) for the majority of these studies because, like immor-
talized DMVEC, KSHV-infected iLEC can be maintained in vitro
for the extended periods required for the establishment of viral
latency (41). To initiate these mechanistic studies, iLEC were in-
fected with BAC-derived WT KSHV (BAC16-WT) and cultured
for 6 days to allow the establishment of latency. Cells were fixed,
immunostained for both the viral latency protein LANA-1
(LANA) and HO-1, and then evaluated by deconvolution micros-
copy (Fig. 1A). Control cells expressed low basal levels of HO-1,
with sporadic cells expressing slightly larger amounts. In contrast,
infected cells, which were identified by LANA and green fluores-
cent protein (GFP) positivity, consistently expressed significantly
higher levels of HO-1. In both mock-infected and virus-infected
cells, HO-1 was localized predominantly to the cytoplasm, reflect-
ing its well-characterized endoplasmic reticulum localization
(42). Importantly, this pattern was also observed in mock-infected
and KSHV-infected primary LEC (see Fig. S1A in the supplemen-
tal material). To determine the kinetics of HO-1 expression in
infected iLEC, we performed a time course experiment measuring
HO-1 mRNA (Fig. 1B) and protein (Fig. 1C) levels at sequential
times postinfection. Using a reverse transcription-quantitative
PCR (qPCR) assay, we observed induction of HO-1 mRNA as
early as 4 h postinfection (hpi). This early burst of expression was
followed by a decline to basal levels by 24 hpi. Subsequently, co-
incident with the establishment of latency, HO-1 was reinduced,
reaching a sustained phase of expression by 3 days postinfection
(dpi) that persisted with time (Fig. 1B). HO-1 protein levels fol-
lowed similar biphasic kinetics, with an early peak of expression at
6 to 8 hpi and sustained expression during latency (3 to 21 dpi).
Parallel extended time course experiments with uninfected cells
confirmed that long-term culture of iLEC had no impact on HO-1
expression (see Fig. S1B). Thus, data from these experiments con-
firm that, similar to what we have previously described in both
primary and transformed DMVEC (7), HO-1 is induced during
KSHV latency. In addition, we now show that KSHV also alters
HO-1 expression during the initial stages of de novo infection.
Our observation that the initial peak of HO-1 expression oc-
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curs within 4 h of virus exposure suggests that early HO-1 induc-
tion is independent of viral gene expression. Instead, HO-1 ex-
pression is likely to be triggered by a component(s) of the virus
particle. To test this hypothesis, a time course experiment was
performed in which iLEC were infected with either live or UV-
inactivated BAC-derived KSHV. Samples were harvested at early
times postinfection and then tested for both HO-1 mRNA
(Fig. 1D) and protein (Fig. 1E) levels. The efficacy of UV inactiva-
tion was confirmed by our inability to detect both latent (LANA)
and lytic (open reading frame 59 [ORF59]) viral transcripts from
cells infected with UV-treated viral preparations (see Fig. S2A in
the supplemental material). This finding was further corroborated
by the lack of KSHV gene expression and the absence of HO-1
induction by UV-inactivated KSHV at later times postinfection
(see Fig. S2B). Interestingly, at early times (0 to 24 h) postinfec-
tion, both live and UV-inactivated KSHV induced HO-1 to equiv-
alent levels and with similar kinetics, indicating that de novo ex-
pression of viral genes is not required for the early peak of HO-1
expression. These experiments suggest that one or more compo-
nents of the viral particle itself are responsible for the early tran-
sient expression of HO-1.
KSHV miR-K12-11 contributes to HO-1 induction during
latent infection of LEC. It was recently reported that exogenous
expression of KSHV-encoded miR-K12-11 was sufficient to in-
duce HO-1 protein expression in 293 cells and that BACH1 levels
were concomitantly reduced (43). In order to determine if miR-
K12-11 influenced HO-1 levels in the context of de novo KSHV
infection of LEC, we made use of a BAC16-derived KSHV mutant
that no longer expressed functional miR-K12-11 (generously pro-
vided by Rolf Renne, University of Florida, Gainesville, FL). This
mutant was generated by deleting one arm of the pre-miRNA,
which prevents maturation to the active miRNA (44). For these
experiments, iLEC were infected with the WT or a mutant virus
lacking either miRNA-K12-11 or miRNA-K12-1 (included as a
control mutant virus; also provided by Rolf Renne) and then cul-
tured for 6 days to allow the establishment of stable latency.
Proper expression of miR-K12-11 in WT virus-infected cells was
confirmed by stem-loop qPCR assay (see Table S1 in the supple-
FIG 1 KSHV infection induces a biphasic induction of HO-1 in LEC. (A) IFA of mock-infected and KSHV-infected iLEC at 6 dpi. Top panels: LANA (red),
HO-1 (green), and DAPI (blue). Bottom panels: GFP (grayscale, same cells as those shown in the top panels). The left panels correspond to mock-infected cells,
and the right panels correspond to KSHV-infected cells. Images were captured at 60 magnification (scale bar, 30 m). (B) qPCR assay of mRNA levels for HO-1
in KSHV-infected iLEC at various times postinfection. Message levels are normalized to the GAPDH level, and fold change was calculated relative to mock-
infected samples at each time point (n  3). (C) WB assay showing HO-1 protein levels in KSHV-infected iLEC at various times postinfection. GAPDH was used
as a loading control. (D) qPCR assay of HO-1 mRNA levels in iLEC infected with either live or UV-inactivated KSHV. Cells were collected for analysis at the
indicated times postinfection (n  3). (E) A WB showing HO-1 protein levels in iLEC infected with either live or UV-inactivated KSHV. Cells were collected at
the indicated times postinfection. GAPDH was used as a loading control.
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mental material). Compared to iLEC infected with either the WT
or the control mutant (K12-1), we observed significantly lower
levels of HO-1 mRNA and protein (Fig. 2A and B) in iLEC infected
with the K12-11 mutant. Although HO-1 expression in K12-11
mutant-infected cells was substantially reduced, some induction
above basal levels in mock-infected cells was observed, indicating
that KSHV induction of HO-1 during latency is not regulated
exclusively by miR-K12-11. Flow cytometric analysis (Fig. 2C) of
KSHV-infected (GFP-positive) iLEC confirmed the reduced
HO-1 levels in cells infected with the K12-11 mutant. Similarly,
an indirect immunofluorescence assay (IFA) (Fig. 2D) demon-
strated a clear decrease in cytoplasmic HO-1 expression in
K12-11 mutant-infected cells. In summary, these experiments
support a key role for miR-K12-11 in HO-1 induction during
latent KSHV infection of LEC. At the same time, our data show
that additional viral and/or cellular factors contribute to maximal
HO-1 expression in latently infected cells. Since miR-K12-11 is a
viral ortholog of miR-155, we also considered the possibility that
KSHV infection could influence the expression of miR-155 in
LEC. In keeping with a previously published study with B cells,
however (31), the expression of miR-155 in LEC was unaffected by
KSHV infection (see Fig. S3 in the supplemental material).
Exogenous miR-K12-11 restores HO-1 expression in KSHV
K12-11 mutant-infected LEC. To provide further support for
the hypothesis that miR-K12-11 plays a role in HO-1 induction
during latent KSHV infection of LEC, a miR-K12-11 mimic was
tested for the ability to complement the HO-1 induction defect
observed for the K12-11 mutant virus. This was accomplished by
infecting iLEC with either WT or K12-11 virus for 6 days, trans-
fecting the cells with 100 ng of either a negative-control miRNA or
a miR-K12-11 mimic, and then testing for levels of both HO-1 and
miR-K12-11 at 24 hpi. Confirming the results shown in Fig. 2, in
FIG 2 The KSHV K12-11 mutant induces reduced levels of HO-1 in latently infected LEC. Time course experiments show HO-1 protein and mRNA levels at
6 dpi in iLEC infected with WT or K12-11 or K12-1 mutant (as a control) KSHV (n  3). (A) qPCR assay results. n.s., not significant, **, P 0.01. A one-way
ANOVA was used for statistical analysis. (B) WB analysis. GAPDH was used as a loading control. (C) Flow cytometric analysis of infected cells gated on GFP. (D)
IFA images. Top panels: HO-1 (green), LANA (red), and DAPI (blue). Bottom panels: GFP in grayscale (same cells as those shown in top panels). Images were
captured at 60 magnification (scale bar, 30 m).
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cells infected with the K12-11 mutant and then transfected with
the control miRNA, HO-1 message (Fig. 3A) and protein (Fig. 3B)
levels were 3- to 4-fold lower than those in similarly transfected
cells infected with the WT virus. Conversely, in the presence of the
miR-K12-11 mimic, HO-1 levels in K12-11 mutant-infected
cells were restored to levels approaching those seen in cells in-
fected with the WT virus. Transfection of mock-infected cells with
the miR-K12-11 mimic was sufficient to induce the HO-1 message
and protein (Fig. 3A and B), which demonstrates that the KSHV
miRNA alone is able to induce HO-1 expression. Stem-loop qPCR
assay results (Fig. 3C) confirmed that the expression levels of miR-
K12-11 in transfected cells were comparable to those in cells in-
fected with the WT virus.
The HO-1 transcriptional repressor BACH1 is downregu-
lated and redistributed in KSHV-infected LEC. As discussed
above, the function of BACH1 is influenced by both its abundance
and its subcellular localization. It has been previously shown that
BACH1 protein levels are low in the stably KSHV-infected PEL
cell line BCBL-1 and that miR-K12-11 plays a role in this pheno-
type (45). However, since BACH1 levels have not been examined
in the context of a de novo KSHV infection in EC, we investigated
BACH1 expression in LEC at 6 dpi with either WT or K12-11
mutant virus. While WT-infected iLEC expressed significantly less
BACH1 mRNA (Fig. 4A) and protein (Fig. 4B) than mock-
infected cells did, BACH1 levels were not significantly reduced in
cells infected with the K12-11 mutant. Interestingly, IFA re-
vealed that in KSHV-infected cells, BACH1 was consistently redis-
tributed to the cytoplasm and that this redistribution occurred
even in the absence of miR-K12-11 (Fig. 4C). Thus, our data in-
dicate that de novo KSHV infection of LEC results in a decrease in
the total BACH1 protein, dependent on miR-K12-11, and in its
redistribution to the cytoplasm, which appears to be miR-K12-11
independent. The identities of the other viral and/or cellular com-
ponents that are responsible for BACH1 relocalization are under
investigation.
To further examine the contribution that BACH1 makes to the
downregulation of HO-1 in the context of KSHV infection, we
next asked if ectopic BACH1 expression could overcome KSHV-
induced HO-1 induction in infected iLEC. For these studies, we
expressed BACH1 from the adenoviral vector pAdTET7 (46). Ex-
pression of BACH1 from the adenoviral vector AdBACH1 was
verified by IFA of transduced iLEC (see Fig. S4 in the supplemental
material). In subsequent studies, latently infected iLEC were
transduced with AdBACH1 or with the transactivator only (trans,
as a control), and then HO-1 levels were examined 1 day later. In
cells not infected with KSHV, adenoviral expression of BACH1
reduced basal HO-1 protein levels below the limit of detection
(Fig. 4E), while mRNA levels could not be further reduced below
the existing detection threshold (Fig. 4D). In KSHV-infected cells,
the high levels of HO-1 message and protein that we typically
observe were significantly reduced by BACH1 overexpression.
Thus, our data show that ectopic expression of BACH1 can effec-
tively overcome KSHV-dependent HO-1 induction.
KSHV induces HO-1 in LEC at early times postinfection in a
miRNA-independent manner. Figure 1 shows that that as early as
4 hpi, KSHV transiently induces HO-1 and that this induction
does not depend upon de novo viral gene expression. A previous
study has shown that KSHV miRNAs, including miR-K12-11, can
be detected in viral particles and that these miRNAs remain active
even after UV inactivation (47). In light of this finding, we asked if
miR-K12-11 could be delivered to host cells within the virus par-
ticle, thereby inducing the early peak of HO-1 expression. We first
examined purified virus preparations for their miRNA content,
and we found that a standard, purified WT virus preparation
FIG 3 Exogenous expression of miR-K12-11 partially restores HO-1 induction
in K12-11 mutant-infected LEC. iLEC were sequentially infected with WT or
K12-11 mutant KSHV for 6 days, transfected with a miR-K12-11 mimic, and
then incubated for another 24 h. Samples were then harvested and prepared for
various HO-1 assays. (A) qPCR analysis. For each sample, the data were normal-
ized to the GAPDH level and the fold change was determined relative to the mock-
infected sample (n  3). n.s., not significant; ***, P  0.0001; *, P  0.05. A
one-way ANOVA was used for statistical analysis. (B) WB assay showing HO-1
protein levels. GAPDH was used as a loading control. (C) Demonstration of miR-
K12-11 levels as determined by stem-loop qPCR assay. miR-K12-11 levels are
normalized to the expression of the internal control miR-16 (n  3).
KSHV Induction of HO-1 in Endothelial Cells














FIG 4 BACH1 levels and subcellular location are altered in KSHV-infected LEC. (A to C) iLEC were mock infected or infected with either the WT or K12-11
mutant virus, samples were harvested at 6 dpi, and then BACH1 levels were determined. (A) qPCR analysis. The raw data for each sample were first normalized
to those for GAPDH. The normalized data were then compared to those for the mock-infected sample in order to determine the fold change (n  6). n.s., not
significant; *, P 0.05. Significance was determined with a Kruskal-Wallis test. (B) BACH1 WB assay. GFP expressed by the virus was used as marker of infection;
GAPDH was used as a loading control. (C) IFA images. Top row, DAPI (blue) and BACH1 (green); bottom row, BACH1 (green) and LANA (red). Labels at the
top of each panel correspond to the viruses used. Images were recorded at 60 magnification; scale bar, 30 m. (D and E) iLEC were first infected with the WT
virus for 6 days and then transduced with either trans (control) or both trans and AdBACH1. Cells were harvested after a further 24-h incubation, and samples
were prepared for either qPCR or WB assays (n  3). (D) qPCR analysis of HO-1 levels. n.s., not significant; ***, P 0.001; **, P  0.01. Significance was assessed
with a one-way ANOVA. (E) WB showing exogenous BACH1 (FLAG) and endogenous HO-1 protein levels. GAPDH was used as a loading control.
Botto et al.














(100 l) contained detectable levels of miR-K12-11, as well as
other representative miRNAs and mRNAs (see Table S2 in the
supplemental material). As expected, miR-K12-11 was not de-
tected in the K12-11 virus preparation, but we did observe mea-
surable levels of other miRNAs and mRNAs therein. Using sam-
ples collected at multiple intervals over the first 24 hpi, we used a
stem-loop qPCR assay to measure miRNA levels in iLEC infected
with the live or UV-inactivated WT virus (Fig. 5A). Interestingly,
despite the capacity of the UV-inactivated virus to induce early
transient HO-1 (Fig. 1D and E), no miR-K12-11 was detected in
cells infected with the UV-inactivated virus; cells infected with the
live virus showed appreciable levels of the miRNA only by 12 hpi,
presumably as a consequence of de novo transcription. Thus, con-
sidering the small inoculum volume used for KSHV infection (less
than 1 l of the stock preparation) and the inability to detect any
miR-K12-11 prior to 12 hpi, our data suggest that miR-K12-11 is
not responsible for the early HO-1 induction seen. In order to
confirm this conclusion, iLEC were infected with the WT virus or
the K12-11 or K12-1 mutant virus, and HO-1 levels were de-
termined at early times postinfection (Fig. 5B and C). As expected,
we were unable to detect miR-K12-11 in K12-11 mutant-
infected iLEC (see Fig. S5 in the supplemental material). HO-1
FIG 5 KSHV miR-K12-11 is not responsible for the early peak of HO-1 induction. (A to C) Time course experiments in which iLEC were infected with KSHV and then
harvested at the indicated times thereafter. (A) Stem-loop qPCR assay of miR-K12-11 in cells infected with either live or UV-inactivated virus. miR-K12-11 expression
is normalized to levels of the cellular internal control miR-16 (n  3). (B) qPCR assay showing HO-1 mRNA levels (n  3) in cells infected with WT or K12-11 or
K12-1 mutant (as a control) KSHV. (C) WB showing HO-1 protein levels in mock-infected cells (M) or cells infected with the WT or K12-11 (K11) or K12-1
(K1) mutant (control) virus. The KSHV-encoded ORF45 protein was used as a marker of infection. GAPDH served as a loading control.
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levels in K12-11 mutant-infected iLEC were, however, compa-
rable to those in cells infected with the WT and K12-1 mutant
viruses, confirming that this miRNA does not play a role in the
early transient induction of HO-1 in KSHV-infected cells. Given
the role of BACH1 in the negative regulation of HO-1 (Fig. 4), we
also considered that BACH1 could influence early HO-1 expres-
sion independently of miR-K12-11 action. Thus, we examined the
expression of BACH1 in KSHV-infected LEC over the first 8 h of
infection (see Fig. S6). BACH1 expression was unaffected during
that time, indicating that early induction of HO-1 is not as a con-
sequence of BACH1 downregulation.
DISCUSSION
In the present study, we confirmed HO-1 upregulation in LEC
infected with a BAC-derived KSHV. Under basal conditions,
HO-1 expression is tightly regulated by the transcriptional repres-
sor BACH1 (48). BACH1 mRNA is downregulated by KSHV
through the action of the viral miRNA miR-K12-11, which targets
the BACH1 3= untranslated region (22, 23). It was recently shown
that exogenous expression of miR-K12-11 in 293 cells is sufficient
for both the induction of HO-1 and the concurrent downregula-
tion of BACH1, suggesting an inverse correlation of the regulation
of these two proteins (43). Our present study is the first to dem-
onstrate that miR-K12-11 also targets BACH1 during de novo in-
fection of LEC, with a concomitant increase in HO-1. Impor-
tantly, however, HO-1 levels in LEC infected with KSHV lacking
miR-K12-11 (K12-11) are not restored to those in mock-
infected cells, indicating that the viral miRNA is not the sole ele-
ment responsible for the modulation of this antioxidant pathway.
It is not uncommon for viruses to adopt more than one mecha-
nism to regulate key cellular proteins and pathways. Therefore, it
is likely that other viral and/or cellular components modulate the
expression of BACH1 and/or other HO-1 regulators, such as the
transcriptional activator NRF2 (26, 49, 50). NRF2 (also known as
NFE2L2) is a member of the basic region leucine zipper protein
family and, as described above, plays a critical role in the induction
of oxidative-stress-responsive genes such as HO-1 (26, 51). Con-
sequently, it is plausible that KSHV has developed the ability to
modulate HO-1 expression by regulating both BACH1 and NRF2.
A recent report suggested that the KSHV latency protein vFLIP, by
virtue of its ability to induce NRF2 during latent infection of hu-
man dermal microvascular EC (HMVEC-d) (52) could provide
yet another means whereby KSHV modulates HO-1 expression.
Another intriguing result is our finding that the subcellular
localization of BACH1 is altered by KSHV infection of LEC, with
a percentage of the predominantly nuclear protein being redis-
tributed to the cytoplasm; as previously stated, BACH1 functions
as a HO-1 transcriptional repressor when bound to the HO-1 pro-
moter in the nucleus. Accordingly, KSHV could also impair
BACH1-mediated repression of ARE-containing genes such as
HO-1 by preventing its translocation to the nucleus or inducing its
nuclear export. Further investigation is needed to evaluate how
KSHV mediates the relocalization of BACH1 and to identify the
viral and/or host factors involved.
While investigating the kinetics of HO-1 expression in de novo-
infected LEC, we discovered that HO-1 is also rapidly and tran-
siently upregulated at early times postinfection (6 to 8 hpi). This
early induction was not dependent on de novo expression of viral
genes, since UV-inactivated virus induced similar levels of HO-1.
This suggests that one or more virion components might be re-
sponsible for the transient upregulation seen. A recent paper dem-
onstrated the presence of biologically functional viral miRNAs in
KSHV virions (47). Thus, we investigated whether miR-K12-11
was also responsible for the early induction of HO-1. Despite the
detection of miR-K12-11 in stock virus preparations, our data
indicate that this viral miRNA is not responsible for the early
induction of HO-1. Consequently, we predict that another virion
component(s) is responsible for the early induction of HO-1.
Since cellular pathways regulated by early de novo KSHV infection
are thought to participate in the orchestration of effective viral
infection (53), it is reasonable to speculate that early induction of
HO-1 by KSHV could protect the cell from virus-induced oxida-
tive stress and contribute to a cellular environment permissive for
successful infection. The recent finding that NRF2 induction in
KSHV-infected HMVEC-d is regulated by early de novo infection
events, including virus binding and early signaling (52), suggests
that KSHV induction of NRF2 contributes to the early HO-1 peak
seen in KSHV-infected LEC. The long-term goal of our studies is
to develop a novel therapy for KS. Because of the selective pressure
on the virus that can lead to mutations within its genome, drug
resistance is a recurrent problem when targeting viral genes (54,
55). Therefore, a more attractive strategy involves the identifica-
tion of cellular genes that are uniquely expressed or overexpressed
during the development of the pathology. HO-1 may represent
such a target for the treatment of KS: HO-1 is selectively upregu-
lated in KS spindle cells (7), KS lesions are characterized by high
free heme and hemoglobin levels as a result of erythrocyte extrav-
asation and degradation (56–58), and HO-1 induction affords
survival and proliferation advantages to infected cells within the
unique tumor microenvironment that would otherwise be hostile
to normal cells. For these reasons and because HO-1 targeting has
been successful in the treatment of other types of cancer, we pro-
pose that a similar approach should be considered for the treat-
ment of KS.
MATERIALS AND METHODS
Cells and viruses. Primary adult human LEC were obtained from Lonza
(Allendale, NJ). iLEC were generated from these cells via transduction
with a retrovirus expressing papillomavirus E6/E7 as previously described
(41). LEC were cultured in EGM-2 medium prepared by supplementing
basal medium (EBM-2; Lonza) with 10% fetal bovine serum (FBS),
penicillin-streptomycin–L-glutamine (PSG; HyClone, Logan, UT), and
additional EC growth supplements (EGM-2MV Bullet kit; Lonza).
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS and PSG. Epithelial iSLK cells
(generously provided by Rolf Renne at the University of Florida, Gaines-
ville, FL, with kind permission from Jae Jung at the University of Southern
California, Los Angeles, CA, and Don Ganem at the University of Califor-
nia, San Francisco, CA) were used to produce stocks of recombinant
KSHV (35, 44, 59, 60). iSLK cells were grown in DMEM supplemented
with 10% FBS, PSG, puromycin (1 g/ml), neomycin (200 g/ml), and
hygromycin (1.5 mg/ml). The KSHV BAC clone BAC16 was kindly pro-
vided by Jae Jung (35). KSHV-BAC16 was derived from recombinant
rKSHV.219, which expresses GFP under the control of the human EF1
promoter (61). The independent regulation of GFP and viral gene expres-
sion in this virus leads to occasional cells that express discordant levels of
KSHV and LANA (62, 63). To produce stocks of recombinant KSHV,
iSLK cells harboring BAC16 were treated with doxycycline (1 M) and
sodium butyrate (3 mM) for 72 h. Supernatants were then collected, and
cell debris was removed via low-speed centrifugation. Clarified superna-
tants were then transferred to ultracentrifuge tubes, underlaid with 25%
sucrose in TNE (150 mM NaCl, 10 mM Tris [pH 8.0], 2 mM EDTA
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[pH 8.0]), and centrifuged at 78,000  g for 2 h at 4°C. The resulting
virion pellets were resuspended in TNE. Stocks of BAC16-derived KSHV
were titrated by infecting iLEC with serially diluted virus preparations.
After a 48-h incubation, the cells were harvested and evaluated for GFP
expression via flow cytometry. For latent-infection experiments, the MOI
(multiplicity of infection) was normalized to the volume of viral superna-
tant required for 20% GFP iLEC. For acute-infection experiments,
MOIs corresponding to 80% GFP iLEC were used and centrifugation
was omitted in order to prevent mechanical-stress-induced HO-1 upregu-
lation.
Antibodies and other reagents. HO-1 protein levels were assessed
with a mouse anti-HO-1 monoclonal antibody (MAb; BD Transduction
Laboratories, Franklin Lakes, NJ) at concentrations of 1:1,000 for Western
blotting (WB) and 1:200 for IFA and flow cytometry. An anti-GFP (goat)
horseradish peroxidase (HRP)-conjugated antibody (600-103-215; Rock-
land, Limerick, PA) was used at 1:2,000 in order to detect GFP. Mouse
anti-BACH1 (F-9) antibody (sc-271211; Santa Cruz Biotechnologies,
Santa Cruz, CA) was used at either 1:200 (WB) or 1:100 (IFA). Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) levels were used as WB
loading controls and detected with a mouse anti-GAPDH antibody
(ab8245; Abcam, Cambridge, England) at a concentration of 1:20,000.
Mouse anti-ORF45 antibody (ab36618; Abcam) was used at 1:500 (WB).
A rabbit anti-LANA antibody (UK183), kindly provided by Bala Chan-
dran (Rosalind Franklin University, Chicago, IL) was used at 1:100 for
IFA. For FLAG epitope detection, an anti-FLAG M2 HRP-conjugated
MAb (Sigma, St. Louis, MO) was used at 1:5,000. For WB, donkey anti-
rabbit (sc-2313; Santa Cruz Biotechnologies) or HRP-conjugated goat
anti-mouse (Millipore, Billerica, MA) secondary antibodies were each
used at a concentration of 1:10,000. For IFA, Alexa Fluor 594-conjugated
anti-mouse IgG1 and Alexa Fluor 647-conjugated anti-rabbit secondary
antibodies (both from Invitrogen, Eugene, OR) were used at 1:1,000.
miRNA mimics were transfected into iLEC with Effectene (Qiagen, Va-
lencia, CA). Both the miR-K12-11 mimic (KSHV-miR-K12-11-5p
mirVana miRNA mimic) and the negative-control miRNA (6-
carboxyfluorescein dye-labeled control pre-miR) were purchased from
Ambion (Life Technologies, Carlsbad, CA).
BACH1 adenovirus vector. A FLAG tag was fused to the BACH1 N
terminus by standard PCR techniques. The resulting DNA fragment was
cloned into the adenoviral vector pAdTet7. In this vector, transgene ex-
pression is driven by a minimal cytomegalovirus promoter that is pre-
ceded by multiple Tet repressor binding sites. Expression from this chi-
meric promoter takes place only in the presence of the Tet transactivator,
as well as the absence of tetracycline or doxycycline (a so-called “Tet-off”
system). In this system, the Tet transactivator is expressed from a second
coinfecting adenovirus, here referred to as trans. In all AdBACH1 exper-
iments, cells infected with trans alone were used to control for nonspecific
effects resulting from adenoviral infection (64). Adenovirus was prepared
from these vectors as described previously (46).
Reverse transcription-qPCR assay. Extraction of total RNA was per-
formed with miRNeasy minikits (Qiagen, Valencia, CA), which allow the
isolation of both miRNAs and mRNAs. DNase I (Qiagen) digestion was
included to remove any contaminating DNA from the samples. Total
cDNA was generated from these samples with the SuperScript III First-
Strand Synthesis System (Invitrogen; Life Technologies, Carlsbad, CA).
The following stem-loop PCR primers were used for the reverse transcrip-
tion of miRNAs (stem-loop [SL] reverse transcription) as previously de-
scribed (65): mir-k12-11 SL, 5=-GTCGTATCCAGTGCAGGGTCCGAG
GTATTCGCACTGGATACGACTCGGAC-3=; mir-k12-1 SL, 5=-GTCGT
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCTTA
C-3=; mir16 SL, 5=-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC
ACTGGATACGACCGCCAA-3=; mir-155 SL, 5=-GTCGTATCCAG
TGCAGGGTCCGAGGTATTCGCACTGGATACGACACCCCT-3=. The
following primers were used for qPCR assays of mRNAs: GAPDH F, 5=-
GAAGGTGAAGGTCGGAGT-3=; GAPDH R, 5=-GAAGATGGTGATGG
GATTTC-3=; HO-1 F, 5=-GCCCTTCAGCATCCTCAGTTC-3=; HO-1 R,
5=-GGTTTGAGACAGCTGCCACA-3=; BACH1 F, 5=-TGAGAAGCTGC
AAAGTGAAAAGG-3=; BACH1 R, 5=-CTGCTTTGTCTCACCCAGAGT-
3=; ORF59 F 5=-CGAGTCTTCGCAAAAGGTTC-3=; ORF59 R, 5=-AAGG
GACCAACTGGTGTGAG-3=. The following primers were used for qPCR
assays of miRNAs: miR-K12-11 F, 5=-CGAGCCTTAATGCTTAGCCUG-
3=; miR-K12-1 F, 5=-GCGAGCATTACAGGAAACTGG-3=; miR16 F, 5=-
CGGCAGTAGCAGCACGTAAAT-3=; miR-155 F, 5=-CGCGAGCTTAA
TGCTAATCGTG-3=. The reverse primer used for miRNA detection was
Universal SL Rev (5=-CCAGTGCAGGGTCCGAGGTA-3=). To perform a
qPCR assay, 5 l of cDNA (typically, 1 to 10 ng) was mixed with gene-
specific primers and 12.5 l of Power SYBR green PCR master mix (ABI,
Foster City, CA) to a final volume of 25 l. Optimization of primer and
sample concentrations was performed for all targets. For qPCR assay ex-
periments, standard curves were set up with appropriate control samples
and a dilution series ranging from 100 ng to 3.2 pg of cDNA. Sample
amplification was performed with an ABI real-time PCR 7500 system. For
relative quantitation experiments, the signal for each cDNA was normal-
ized to GAPDH levels, thereby allowing the comparison of mRNA expres-
sion levels in different samples.
WB analysis. Cells were lysed in radioimmunoprecipitation assay buf-
fer (50 mm Tris [pH 7.5], 150 mm NaCl, 1% Nonidet P-40, 0.5% deoxy-
cholate, 0.1% SDS, 1 Complete inhibitors [Roche Applied Science,
Pleasanton, CA]), incubated on ice for 30 min, and then centrifuged at
13,400  g for 10 min at 4°C. Cleared supernatants were transferred to
fresh tubes, and their protein concentrations were determined via bicin-
choninic acid assay (Thermo Fisher Scientific, Waltham, MA). The result-
ing proteins were separated via reducing SDS-PAGE, transferred to poly-
vinylidene difluoride membranes, incubated in blocking buffer (5%
nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 [TBST]) for
1 h with agitation, and then probed with the appropriate primary anti-
body diluted in blocking buffer. Blots were then washed three times with
TBST, incubated with the appropriate secondary antibodies in blocking
buffer, and then washed a further three times with TBST. Blots were de-
veloped with an ECL Plus kit (Amersham Biosciences/GE Healthcare,
Pittsburgh, PA), and the resulting data were captured with either Kodak
XAR film or a G:BOX (Syngene). The ImageJ software package (ImageJ;
National Institutes of Health, Bethesda, MD; http://imagej.nih.gov/ij/)
was used for band quantitation. The images shown are representative of
three independent experiments.
IFA and image analysis. For IFA, cells were seeded onto collagen-
coated coverslips (BD Biosystems, Franklin Lakes, NJ) in six-well tissue
culture plates. At the end of the experiment, cells were fixed in 2% para-
formaldehyde for 8 min, washed three times in phosphate-buffered saline
(PBS), and permeabilized in 0.25% Triton X-100 for 8 min. Cells were
blocked in IFA blocking buffer (20% normal goat serum [NGS] in PBS)
for 20 min at 37°C and incubated with the appropriate primary antibody
incubation buffer (1% NGS in PBS) for 1 h at 37°C. After primary anti-
body incubation, coverslips were washed three times in PBS and incu-
bated with both the appropriate secondary antibody and the nuclear stain
4=,6-diamidino-2-phenylindole (DAPI) for 45 min at 37°C. Coverslips
were then washed three times in PBS and mounted on glass slides with
Fluoromount-G (Southern Biotech, Birmingham, AL). The slides were
then analyzed with a DeltaVision real-time deconvolution fluorescence
microscope (Applied Precision, Issaquah, WA), and images were cap-
tured with a Photometrics CoolSNAP HQ camera. Image analysis was
performed with SoftWoRx (Applied Precision). Stacks of images (0.2-m
z step) were captured at 60 magnification. Stacks were subjected to
deconvolution, and two- or three-section projections were made by su-
perimposing representative z planes to generate the final image. Images
shown are representative of three independent experiments. Where nec-
essary to facilitate visualization of GFP and more than one fluorescently
tagged target protein of interest, GFP was pseudocolored to grayscale.
Flow cytometry. Cells to be analyzed via flow cytometry were dissociated
from tissue culture plates with nonenzymatic Cellstripper (25-056-CI; Cell-
gro/Corning, Manassas, VA) and then pelleted at 1,800  g at 4°C for 5 min.
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The cells were fixed with BD Cytofix/Cytoperm, incubated on ice for 15 min,
pelleted, and then resuspended in 1 BD Permwash containing the primary
antibody. After a further 15-min incubation on ice, the cells were washed
three times and then resuspended in 1 BD Permwash containing the appro-
priate dilution of the secondary antibody. After a subsequent 15 min on ice,
the cells were washed in 1 BD Permwash and finally analyzed on a BD
FACSCalibur flow cytometer (BD Biosciences).
Statistical analysis. Quantitative PCR data are expressed as the mean
 the standard error of the mean (SEM). Statistical analysis was per-
formed with R software (R Core Team, Vienna, Austria). One-way anal-
ysis of variance (ANOVA) and Kruskal-Wallis tests were used to compare
means of different groups.
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